GlaxoSmithKline appeared to be the Corporate Investor, which was created in 1929. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the Middlesex.
The higher amount of exits for fund were in 2019. Comparing to the other companies, this GlaxoSmithKline performs on 4 percentage points more the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2015. The real fund results show that this Corporate Investor is 19 percentage points more often commits exit comparing to other companies. When the investment is from GlaxoSmithKline the average startup value is more than 1 billion dollars. The fund is constantly included in less than 2 deals per year.
The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Biopharma, Intellectual Property. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline 23andMe, Genmab, NeuroTherapeutics Pharma
The overall number of key employees were 14.
The typical case for the fund is to invest in rounds with 4 participants. Despite the GlaxoSmithKline, startups are often financed by Three Arch Partners, TVM Capital, Skyline Ventures. The meaningful sponsors for the fund in investment in the same round are SR One, Avalon Ventures, The Kraft Group. In the next rounds fund is usually obtained by Wellington Management, SR One, OUP (Osage University Partners).
Related Funds
Funds with similar focus
| Fund Name | Location |
| 51job | China, Shanghai |
| Central Investments | - |
| CITICS Prosperity Fund | Beijing, Beijing, China |
| Deshe Holdings | Florida, Miami Beach, United States |
| DWS Group | Frankfurt, Germany, Hessen |
| DWS investment | Frankfurt, Germany, Hessen |
| KOEI TECMO GAMES | Japan, Kanagawa Prefecture, Yokohama |
| Ocean IQ Partners | - |
| Tmeng.cn | Beijing, Beijing, China |
Angela Kwan Finance Lead u2013 Mergers, Acquisitions and Divestments (MA&D) b7f2530f47c ee76e615be5a19343908fa89cab9b796 1d27f6ace 4c05b0c77119b3314be7cfcfee9b28d0 c054d33e728 7c339687308b37a1f60c296879f26e66 4eb15da329d8 c04abc0ecd575d15092b938c33f 970c56800d9 d94f66b82d42d02d5dbc4d100344d094 
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Asceneuron | $100M | 16 Jul 2024 | Lausanne, Vaud, Switzerland | ||
LifeMine Therapeutics | $175M | 23 Mar 2022 | Cambridge, Massachusetts, United States | ||
Adrestia Therapeutics | $235M | 18 Dec 2020 | South Cambridgeshire, England, United Kingdom | ||
SpringWorks Therapeutics | $125M | 01 Apr 2019 | Stamford, Connecticut, United States | ||
Spero Therapeutics | $30M | 02 Feb 2016 | Cambridge, Massachusetts, United States | ||
Atreca | $56M | 04 Nov 2015 | California, United States | ||
Gladius Pharmaceuticals | $3M | 23 Jun 2015 | Canada, Montreal | ||
Spero Therapeutics | $30M | 08 Jun 2015 | Cambridge, Massachusetts, United States | ||
Thyritope Biosciences | $10M | 22 Sep 2014 | San Diego, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Asceneuron | $100M | 16 Jul 2024 | Lausanne, Vaud, Switzerland | ||
LifeMine Therapeutics | $175M | 23 Mar 2022 | Cambridge, Massachusetts, United States | ||
Adrestia Therapeutics | $235M | 18 Dec 2020 | South Cambridgeshire, England, United Kingdom | ||
SpringWorks Therapeutics | $125M | 01 Apr 2019 | Stamford, Connecticut, United States | ||
Spero Therapeutics | $30M | 02 Feb 2016 | Cambridge, Massachusetts, United States | ||
Atreca | $56M | 04 Nov 2015 | California, United States | ||
Gladius Pharmaceuticals | $3M | 23 Jun 2015 | Canada, Montreal | ||
Spero Therapeutics | $30M | 08 Jun 2015 | Cambridge, Massachusetts, United States | ||
Thyritope Biosciences | $10M | 22 Sep 2014 | San Diego, California, United States |
